Skip to main content

Deal Alert: Pharma firm Themis Labs raises Rs. 90-Cr from NYLIM India

From Press Release:

Themis Laboratories Private Limited (Themis Laboratories), India’s leading pharmaceutical company specializing in developing and manufacturing of pharmaceutical formulations using novel drug delivery systems (“NDDS”), today announced that the company has received an equity investment of INR 900 million from NYLIM Jacob Ballas India Fund III, LLC (“NYLIM Jacob Ballas India Fund”), a Mauritius based Private Equity investor.

Commenting on the deal, Mr. Janak Shah, Chairman, Themis Laboratories, said, “Themis Laboratories has emerged as one of India’s leading novel drug delivery companies with a robust pipeline backed by a strong research and development (“R&D”) setup. This investment by NYLIM Jacob Ballas India Fund would help strengthen the company’s foray into the regulated markets. We believe this partnership will help us realize our vision to be a significant player in the global NDDS space.”

He further added that the investment would be utilized to finance the setting up of a new R&D facility and to establish a marketing network in overseas export markets.

Bharat Bakhshi, Partner, Jacob Ballas Capital India Pvt Ltd (“JBC”), investment advisor to NYLIM Jacob Ballas India Fund, said “Themis Laboratories has developed long term relationships with leading pharmaceutical companies in India for developing and manufacturing NDDS formulations owing to its strong technical expertise and its commitment to high quality standards and regulatory compliance. Given the numerous benefits offered by NDDS formulations we are confident that Themis Laboratories will show continued success and we look forward to being a partner in this success.” Mr Bakhshi has joined the Board of Directors of Themis Laboratories.

JBC, based in New Delhi, is the investment advisor to three India focused private equity funds, New York Life International India Fund (Mauritius), LLC, New York Life Investment Management India Fund II LLC and NYLIM Jacob Ballas India Fund III, LLC.

About Themis Laboratories

Mumbai-based Themis Laboratories Private Limited is India’s leading pharmaceutical company specializing in developing and manufacturing of pharmaceutical formulations using NDDS. Themis Laboratories has expertise in developing sustained release formulations, controlled release formulations, combination products, taste masking formulations and oral fast dissolving dosage forms. Themis Laboratories supplies NDDS formulations and intermediates to leading domestic pharmaceutical companies and Indian arms of global pharmaceutical companies. It has recently set up a new manufacturing facility in Ambernath, which is designed to meet international regulatory standards. The company has a dedicated R&D centre in Thane which is approved by the Department of Science & Technology, Government of India. For more information please visit www.themislabs.com. Themis Laboratories was promoted by Mr. Janak Shah and Mrs. Maya Shah in 1985.

About NYLIM Jacob Ballas India Fund

NYLIM Jacob Ballas India Fund III, LLC is a Mauritius based fund with an investment objective of achieving long-term capital appreciation through equity or equity-related investments into companies based in or with significant operations in India. Previous investments by the Fund include Aster Teleservices Limited, Mahindra Holidays & Resorts India Limited and Saravana Global Energy Limited. Affiliate funds of NYLIM Jacob Ballas India Fund have previously invested in a diverse range of sectors including telecom, ports, power, engineering construction, shipbuilding, real estate, textiles, auto components, IT consulting and printing.

About Jacob Ballas Capital India Pvt Ltd

Jacob Ballas Capital India Pvt. Ltd (“JBC”), based in New Delhi, is the investment advisor to three India focused private equity funds, New York Life International India Fund (Mauritius), LLC, New York Life Investment Management India Fund II LLC and NYLIM Jacob Ballas India Fund III, LLC. JBC’s ten member investment team has over 140 years of collective operating and investing experience, with over 40 years focused on private equity investments in India.

JBC was founded by Mr Rajan Jetley, Chairman, who is a well known professional and entrepreneur. Mr Jetley, Chairman of JBC, has previously served as CEO of Air India and India Tourism Development Corporation, and as Director of International Airports Authority of India. JBC’s shareholders, apart from Mr Jetley, include NYLCAP Holdings (Mauritius) which is wholly owned by New York Life Investment Management Holdings LLC, a wholly owned subsidiary of New York Life Insurance Company, Excelfin, promoted by Mr B S Ong and Mr David Ban, reputed Asian entrepreneurs with extensive interests in property, retail and lifestyle businesses and Indtech Constructions Pvt Ltd, promoted by Mr Atul Punj, Chairman of Punj Lloyd Ltd, one of India’s leading engineering construction conglomerates. For more information please visit www.jbindia.co.in.

Popular posts from this blog

PE-VC investments in Q2'23 decline 33% to $9.9 Billion

Private Equity-Venture Capital (PE-VC) investments in India during the quarter ended June 2023 (Q2'23), at $9.85 Billion across 182 deals, registered a 33% decrease compared to the same period in 2022 (which saw $14.6 Billion being invested across 371 deals). The investment amount however rose 74% compared to the immediate previous quarter (which saw $5.7 Billion being invested across 181 deals), shows data from  Venture Intelligence , a research service focused on private company financials, transactions, and their valuations. The PE-VC investment figures for the first 6 months of 2023 - at $15.5 Billion (across 363 deals) - was 50% lower compared to the same period in 2022 (which saw $31 Billion being invested across 800 deals). Q2’23 witnessed 19 mega deals ($100 M+

Chiratae, Speciale and Stride Ventures win APEX'24 Venture Capital Awards

Chiratae Ventures, Speciale Invest and Stride Ventures were awarded as among the leading Venture Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) VC Investor of the Year Chiratae Ventures received the Venture Capital Investor of the Year 2023 Award on the back of 10 part exits totaling $178 million via Secondary Sales during the year. Its exits included those from retail unicorn Lenskart, SaaS Startup Pixis and baby pr

Blackstone, MO Alts and InvAscent win APEX'24 Private Equity Awards

Press Release Blackstone, MO Alternates (formerly Motilal Oswal PE) and InvAscent were awarded as among the leading Private Equity and Growth Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) PE Investor of the Year Blackstone received the Private Equity Investor of the Year 2023 Award on the back of strong complete exits during the year: from Sona Comstar and IBS Software. Ganesh Mani and Amit Dalmia, Senior Managing D

Avendus tops League Table for Transaction Advisors to PE deals in Q1'23

Aeka Advisors and Ambit claim the No.2 & 3 slot Avendus topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions for Q1 2023 advising 5 deals worth $808 million. Aeka Advisors stood second having advised 3 deals worth $228 million. Ambit followed with 4 deals worth $160 million. Ernst & Young ($114 million across 4 deals) and o3 Capital ($80 million across 2 deals) completed the top five for Q1 2023. Avendus acted as advisor to ADIA’s $500 million investment in omnichannel eyewear retailer Lenskart . Aeka Advisors acted as advisor to Kreditbee’s $160 million fundraise from Advent International, Mitsubishi UFJ Financial Group (MUFG) and existing investors. Ambit advised the $104 million fundraise of Freshtohome from Mount Judi Ventures, Iron Pillar, Amazon and others. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE

PE-VC investments fall 38% in 2023 to below $30 B

The value of investments by Private Equity - Venture Capital (PE-VC) firms in India fell by 38% to less than $30 Billion in 2023. PE-VC firms invested $29.7 Billion (across 756 deals) in Indian companies in 2023, compared to $47.6 Billion (across 1,362 deals) in the previous year, reports Venture Intelligenc e, a research service focused on private company financials, transactions, and their valuations. (Note: These figures exclude PE investments in Real Estate).                                                                                                                                                                      2023 witnessed 67 mega deals ($100 M+ rounds) worth $21.2 Billion, compared to 112 such investments worth $31.8 Billion in 2022. The $2.4 Billion investment in Manipal Hospitals by Temasek (which gained majority control) and TPG Capital was the largest PE-VC investment in 2023. This was followed by the $1.35 Billion buyout of education loans focused HDFC Credila